AGP Executive Report
Last update: 4 hours agoNew Vision Tech in Europe: The PRIMA retinal implant, designed to restore functional central vision for geographic atrophy (advanced macular degeneration), has been approved for use in Europe, with researchers also exploring other eye conditions. Dutch Health Tech Investor Update: Royal Philips and its largest shareholder Exor (Agnelli family) have updated their long-term agreement, letting Exor raise its stake to up to 22% (from 20%), subject to supervisory board approval for any further increase. Cancer Treatment Research: A new study reports that combining standard therapy with ultrasound-targeted microbubbles can safely shrink advanced liver tumours in patients with aggressive hepatocellular carcinoma. Infectious Disease Pipeline: Tuberculosis vaccine development is accelerating again, with 18 candidates in clinical development and the M72/AS01E vaccine now in a large phase 3 trial. Public Health & Climate: A European review links heavy rainfall and flooding with infectious disease risks, highlighting gaps in surveillance and preparedness.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![[Latest] Global Accelerometer Medical Sensors Market Size/Share Worth USD 2.93 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)](https://ml.globenewswire.com/Resource/Download/6d1bbe3b-d9f1-4cae-9a02-2c4a48362517/accelerometer-medical-sensors-market.png)
